GlassScriptPhysician profile
Melinda J Smith
NPI 1922084086
$1,711.83
in general payments reported to CMS, 2019-2025
21 companies · $47.47 in 2025
The $47.47 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.34 · 2021: $48.29 · 2022: $241 · 2023: $762 · 2024: $541 · 2025: $47.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $438.94 | 2022-2025 | Cardiomems, Mitraclip, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $201.34 | 2023-2024 | |
| Boston Scientific Corporation | $144.77 | 2024 | Watchman Flx |
| Edwards Lifesciences Corporation | $118.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $107.02 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $91.34 | 2024 | Arcalyst |
| Philips North America LLC | $87.88 | 2023-2024 | (5091) Amb Mon & Diag Und |
| Daiichi Sankyo INC. | $69.33 | 2022-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.45 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $51.87 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.89 | 2023 | Lifevest |
| Pfizer INC. | $43.36 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $41.32 | 2024 | Assure Wcd |
| Esperion Therapeutics, INC. | $40.22 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $38.51 | 2019-2024 | Xarelto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.05 | 2021-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $29.48 | 2024 | Onpattro |
| Gilead Sciences, INC. | $26.06 | 2023 | |
| Amarin Pharma, INC. | $19.39 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $15.10 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.59 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melinda Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.